ESMO GI 2024 Highlights Podcast

In this episode [14.18], Medicom’s correspondent covers 6 presentations from annual meeting of the European Society of Medical Oncology Gastrointestinal Cancers Congress 2024 (ESMO GI 2024) held in Munich, Germany 26-29 June 2024.

The topics discussed are:

1. Durvalumab plus chemotherapy enhances 3-year survival in advanced biliary tract cancer
   Prof. Do-Youn Oh (Seoul National University, Korea) presented updated findings from the phase 3 TOPAZ-1 trial, revealing that durvalumab combined with standard-of-care chemotherapy significantly improved 3-year overall survival compared with chemotherapy alone in patients with advanced biliary tract cancer.
2. Lunresertib with FOLFIRI slays in MINOTAUR
   Positive initial data from the ongoing phase 1 MINOTAUR clinical trial, evaluating lunresertib (RP-6306) in combination with FOLFIRI for patients with advanced solid gastrointestinal tumours, indicates an 18.2% overall response rate in heavily pretreated patients with target alterations, regardless of prior irinotecan exposure.
3. REGINA meets stage 1 endpoint and moves to stage 2 with reduced dose regorafenib
   The phase 2 REGINA trial has yielded encouraging results for the use of neoadjuvant regorafenib together with nivolumab and short-course radiotherapy in treating patients with stage II–III rectal cancer, although toxicities were more common than anticipated.
4. High efficacy of pembrolizumab combined with standard therapy in patients with pMMR/MMS mCRC and high immune infiltrate
   Preliminary results of the phase 2 POCHI trial showed high efficacy of pembrolizumab, combined with standard therapy, in patients with microsatellite stable/proficient mismatch repair metastatic colorectal cancer.
5. OS benefit in ARMANI, but is it worth it?
   If patients with HER2-negative advanced gastric or gastroesophageal junction cancer and low/absent PD-L1 expression switch their consolidation maintenance or early second-line therapy from CAPOX/FOLFOX to ramucirumab plus paclitaxel, modest improvements in progression-free survival and overall survival are reported. But toxicities are higher, and if patients progress they would enter third-line therapy. Are the benefits worth it?
6. KEYNOTE-585: negative trial, but long-term benefit in PD-L1-high/MSI subgroups?
   Data from the KEYNOTE-585 trial demonstrates a clear increase in pathological complete responses with peri-operative pembrolizumab plus FLOT versus FLOT alone, but only modest improvements in overall survival.

Enjoy listening!

Copyright ©2024 Medicom Medical Publishers



Posted on 15 July 202421 August 2024